Salud financiera de hoja de balance de Syntara

Salud financiera controles de criterios 5/6

Syntara tiene un patrimonio de los accionistas total de A$4.7M y una deuda total de A$8.0K, lo que sitúa su ratio deuda-patrimonio en 0.2%. Sus activos y pasivos totales son A$10.4M y A$5.7M respectivamente.

Información clave

0.2%

Ratio deuda-patrimonio

AU$8.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$3.52m
Patrimonio	AU$4.68m
Total pasivo	AU$5.70m
Activos totales	AU$10.38m

Actualizaciones recientes sobre salud financiera

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04

Recent updates

Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

Jul 05

Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Apr 29

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Oct 27

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Mar 01

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$9.8M) de SNT superan a sus pasivos a corto plazo (A$5.5M).

Pasivo a largo plazo: Los activos a corto plazo de SNT (A$9.8M) superan a sus pasivos a largo plazo (A$250.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: SNT tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de SNT ha crecido de 0% a 0.2% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: SNT tiene suficiente cash runway para 3 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que SNT disponga de suficiente cash runway para 4 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Syntara

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

Recent updates

Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024

Syntara Limited, Annual General Meeting, Nov 28, 2024

Syntara Limited Announces CFO Changes

Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

New major risk - Financial position

New minor risk - Financial position

New minor risk - Financial position

Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Price target decreased by 41% to AU$0.20

New major risk - Shareholder dilution

Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.

New major risk - Financial position

New minor risk - Financial position

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

New major risk - Revenue and earnings growth

Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

New minor risk - Financial data availability

Price target decreased by 32% to AU$0.17

Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Pharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial

Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study

Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728

Full year 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd to Report Fiscal Year 2022 Final Results on Aug 23, 2022

Pharmaxis Ltd Announces Resignation of Will Delaat as Non Executive Director

Full year 2022 earnings: Revenues miss analyst expectations

Pharmaxis Limited Announces the Appointment of Dr. Jana Baskar as Chief Medical Officer

Pharmaxis Ltd, Annual General Meeting, Jul 11, 2022

Pharmaxis Ltd to Report Fiscal Year 2022 Results on Aug 11, 2022

Price target increased to AU$0.58

Less than half of directors are independent

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Second quarter 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd Announces First Patients Dosed in PXS Scar Reduction Trial

Independent Chairman of the Board recently bought AU$113k worth of stock

First quarter 2022 earnings released: AU$0.007 loss per share

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Pharmaxis Ltd Announces Results of Data Analysis from the Second of Three Stages in Its Phase 1C Clinical Trial (MF-101) Studying Potential New Treatment for the Bone Marrow Cancer Myelofibrosis

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

Pharmaxis Ltd announced that it expects to receive AUD 4.366891 million in funding from Karst Peak Capital Limited, BVF Partners, L.P.

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Analysts lower EPS estimates to -AU$0.014

Pharmaxis Exports CF Drug to US

Second quarter 2021 earnings released

Revenue and earnings miss expectations

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Pharmaxis Receives USD 7 Million Milestone from Chiesi

Pharmaxis Ltd, Annual General Meeting, Nov 03, 2021

Pharmaxis to Present at Proactive CEO Investor Session

First quarter earnings released

Price target lowered to AU$0.09

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera